ATC Group: B01AC Platelet aggregation inhibitors excl. heparin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B01AC in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B01 Antithrombotic agents
3 B01A Antithrombotic agents
4 B01AC Platelet aggregation inhibitors excl. heparin

Group B01AC contents

Code Title
B01AC01 Ditazole
B01AC02 Cloricromen
B01AC03 Picotamide
B01AC04 Clopidogrel
B01AC05 Ticlopidine
B01AC06 Acetylsalicylic acid
B01AC07 Dipyridamole
B01AC08 Carbasalate calcium
B01AC09 Epoprostenol
B01AC10 Indobufen
B01AC11 Iloprost
B01AC13 Abciximab
B01AC15 Aloxiprin
B01AC16 Eptifibatide
B01AC17 Tirofiban
B01AC18 Triflusal
B01AC19 Beraprost
B01AC21 Treprostinil
B01AC22 Prasugrel
B01AC23
B01AC24 Ticagrelor
B01AC25
B01AC26
B01AC27
B01AC28
B01AC30 Combinations
B01AC56

Active ingredients in B01AC

Active Ingredient Description
Abciximab

Abciximab is the Fab fragment of the chimeric monoclonal antibody 7E3. It is directed against the glycoprotein (GP) IIb/IIIa (αIIbβ3) receptor located on the surface of human platelets. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.

Acetylsalicylic acid

Acetylsalicylic acid combines significant advantages such as strong anti-pyretic, analgesic and anti-inflammatory action, that is the measure of comparison with all the newer NSAIDs.

Beraprost
Cangrelor

Cangrelor is a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation in vitro and ex vivo. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signalling and platelet activation.

Carbasalate calcium

Carbasalate calcium is a complex of calcium acetyl salicylic acid and urea. It is a thrombocyte aggregation inhibitor. The antithrombotic effect is due to the irreversible acetylating of the enzyme cyclo-oxygenase in the thrombocyte, through which the formation of the prostaglandin thromboxane A2 is inhibited.

Cilostazol

Cilostazol and several of its metabolites are phosphodiesterase III inhibitors which suppress cyclic AMP degradation, resulting in increased cAMP in a variety of tissues including platelets and blood vessels. Studies in animals and in man (in vivo and ex vivo) have shown that cilostazol causes reversible inhibition of platelet aggregation.

Clopidogrel

Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.

Dipyridamole

Dipyridamole is an antithrombotic agent with antiplatelet activity. Dipyridamole has an antithrombotic action based on its ability to modify various aspects of platelet function, such as platelet aggregation, adhesion and survival, which are factors associated with the initiation of thrombus formation.

Ditazole
Epoprostenol

Epoprostenol sodium, the monosodium salt of epoprostenol, a naturally occurring prostaglandin produced by the intima of blood vessels. Epoprostenol is the most potent inhibitor of platelet aggregation known. It is also a potent vasodilator.

Eptifibatide

Eptifibatide is an inhibitor of platelet aggregation and belongs to the class of RGD (arginine-glycine-aspartate)-mimetics. Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein (GP) IIb/IIIa receptors.

Iloprost

Iloprost is a synthetic prostacyclin analogue. After inhalation of iloprost direct vasodilatation of the pulmonary arterial bed occur with consecutive significant improvement of pulmonary artery pressure, pulmonary vascular resistance and cardiac output as well as mixed venous oxygen saturation.

Indobufen
Limaprost
Prasugrel

Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function can result in the reduction of the rate of cardiovascular events such as death, myocardial infarction, or stroke.

Sarpogrelate
Selexipag

Selexipag is a selective IP receptor agonist distinct from prostacyclin and its analogues. Selexipag is hydrolysed by carboxylesterases to yield its active metabolite, which is approximately 37-fold more potent than selexipag. Stimulation of the IP receptor by selexipag and the active metabolite leads to vasodilatory as well as anti-proliferative and anti-fibrotic effects.

Ticagrelor

Ticagrelor is an oral, direct acting, selective and reversibly binding P2Y12 receptor antagonist that prevents ADP-mediated P2Y12 dependent platelet activation and aggregation. Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function has been shown to reduce the risk of CV events such as death, MI or stroke.

Ticlopidine
Tirofiban

Tirofiban is a non-peptidal antagonist of the GP IIb/IIIa receptor, an important platelet surface receptor involved in platelet aggregation. Tirofiban prevents fibrinogen from binding to the GP IIb/IIIa receptor, thus blocking platelet aggregation.

Treprostinil

Treprostinil is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. Treprostinil had high affinity for the Prostaglandin D2 receptor (DP1), Prostaglandin E2 receptor EP2 subtype (EP2) and Prostaglandin D2 receptor (IP) receptors (Ki 4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, Prostaglandin F (FP) and thromboxane (TP) receptors. Treprostinil has demonstrated a unique effect on PPAR gamma, a transcription factor important in vascular pathogenesis as a mediator of proliferation, inflammation and apoptosis.

Triflusal

Triflusal reduces thromboxan biosynthesis through irreversible inhibition of platelet cyclooxygenase, sparing prostacyclin biosynthesis because its effect on vascular cyclooxygenase at therapeutic doses is negligible.

Vorapaxar

Vorapaxar is a selective and reversible inhibitor of the PAR-1 receptors on platelets that are activated by thrombin.

Related product monographs

Title Information Source Document Type  
ASA Delayed-release tablet Health Products and Food Branch (CA) MPI, CA: SPM
ASPIRIN Gastro-resistant tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ASPIRIN Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ASPIRIN Tablets BP 300mg Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
BRILINTA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
BRILIQUE Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
CAPRIN Gastro-resistant tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
CILOSTAZOL Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CLOPIDOGREL ZENTIVA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
CLOPIVAS Film-coated tablet Web Search MPI, US: SPL/PLR
COPLAVIX Film-coated tablet Marketing Authorisation Holder MPI, Generic
EFFIENT Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
EFIENT Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ILOMEDIN Solution for infusion Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
INTEGRILIN Solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
KENGREXAL Powder for concentrate solution European Medicines Agency (EU) MPI, EU: SmPC
NU-SEALS Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OFCRAM Prolonged release capsules, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PERAZODIN Coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
Persantin 100 mg Tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PERSANTINE Coated tablet FDA, National Drug Code (US) MPI, US: SPL/Old
PLAVIX 75mg Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PLAVIX Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
PLETAL Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
PROCARDIN Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
REOPRO Solution for injection or infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TREPULMIX Solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
UPTRAVI Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
VELETRI Powder for solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VENTAVIS Nebuliser solution European Medicines Agency (EU) MPI, EU: SmPC
ZONTIVITY Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ZYLLT Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC